LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

LLY

1,095.21

-2.64%↓

JNJ

226.73

-2.05%↓

ABBV

216.57

-1.01%↓

UNH

379.19

-1.44%↓

MRK

118.67

-1.27%↓

Home・Akciju saraksts・Incyte Corp

Incyte Corp

Atvērts

SektorsVeselības aprūpe

97.46 0.32

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

96.18

Max

97.77

Galvenie mērījumi
By Trading Economics
Ienākumi	4.1M 303M
Pārdošana	-234M 1.3B
P/E Sektora vidējais	13.723 50.102
EPS	1.81
Peļņas marža	23.834
Darbinieki	2,844
EBITDA	-47M 368M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+11.25% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 28. jūl.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	362M 19B
Iepriekšējā atvēršanas cena	97.14
Iepriekšējā slēgšanas cena	97.46

Ziņu noskaņojums

By Acuity

58%

42%

277 / 344 Rangs Healthcare

Incyte Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. maijs 22:47 UTC

Peļņas

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

2026. g. 28. maijs 20:45 UTC

Peļņas

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

2026. g. 28. maijs 23:43 UTC

Tirgus saruna

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

2026. g. 28. maijs 23:39 UTC

Tirgus saruna

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

2026. g. 28. maijs 23:31 UTC

Tirgus saruna

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

2026. g. 28. maijs 23:17 UTC

Tirgus saruna

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

2026. g. 28. maijs 23:02 UTC

Tirgus saruna

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

2026. g. 28. maijs 22:41 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 28. maijs 22:41 UTC

Tirgus saruna

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

2026. g. 28. maijs 22:37 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

M&A-Related Insurance Payments In North America Rise -- Market Talk

2026. g. 28. maijs 22:04 UTC

Iegādes, apvienošanās, pārņemšana

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

2026. g. 28. maijs 22:04 UTC

Iegādes, apvienošanās, pārņemšana

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

2026. g. 28. maijs 21:12 UTC

Peļņas

Iegādes, apvienošanās, pārņemšana

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

2026. g. 28. maijs 21:00 UTC

Peļņas

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

2026. g. 28. maijs 20:57 UTC

Peļņas

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026. g. 28. maijs 20:55 UTC

Peļņas

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Financial Services Roundup: Market Talk

2026. g. 28. maijs 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 28. maijs 20:48 UTC

Karstas akcijas

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

2026. g. 28. maijs 20:34 UTC

Peļņas

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

2026. g. 28. maijs 20:31 UTC

Peļņas

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

2026. g. 28. maijs 20:28 UTC

Peļņas

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

2026. g. 28. maijs 20:26 UTC

Peļņas

Dell Stock Soars on Blowout Earnings -- Barrons.com

2026. g. 28. maijs 20:20 UTC

Peļņas

Costco 3Q Membership Fees $1.37B

2026. g. 28. maijs 20:20 UTC

Peļņas

Costco 3Q Net Sales $69.15B

2026. g. 28. maijs 20:19 UTC

Peļņas

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

2026. g. 28. maijs 20:19 UTC

Peļņas

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

2026. g. 28. maijs 20:17 UTC

Peļņas

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

2026. g. 28. maijs 20:17 UTC

Peļņas

Costco 3Q Same-Store Sales Up 9.8% >COST

Salīdzinājums

Cenas izmaiņa

Incyte Corp Prognoze

Cenas mērķis

By TipRanks

11.25% augšup

Prognoze 12 mēnešiem

Vidējais 108.29 USD 11.25%

Augstākais 135 USD

Zemākais 75 USD

Pamatojoties uz 19 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Incyte Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

19 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 19 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Incyte Corp — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

277 / 344 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation